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We developed an immunosensor that operates based on the lateral ﬂow principle designed to detect
haemoglobin A1c (HbA1c), a biomarker for type 2 diabetes mellitus in human blood samples. Two
diﬀerent clones of antibodies were used to form a “sandwich” when HbA1c was present.
Functionalization of colloidal gold with antibodies was carefully optimized to generate stable gold
conjugates to amplify the signal from the formed “sandwich” for the immunoassay. The ideal blocking
reagent to minimize background noises, the test line format on the strip, the selectivity of the assay
towards HbA1c against HbA0 and glycated species of HbA0, and the potential interference contributed
by the colour of the blood sample were investigated. Captured HbA1c on the lateral ﬂow immunosensor
can be distinguished based on the number and intensity of the test lines shown; visual detection of the
lines shown then indicated the distinctive groups at normal, under control, and elevated levels of HbA1c.
Also, a calibration curve that covered the detection range of 4% (20 mmol mol1) and 12% (108 mmol
mol1) HbA1c was reported, indicating that the prototype can be used for future quantiﬁcation utilizing a
lateral ﬂow reader. The resultant immunosensor was found to report results that were easier to be
interpreted and relatively inexpensive compared to electrochemical biosensors developed for the
detection of HbA1c.1. Introduction
Haemoglobin A1c (HbA1c) has long been used as a biomarker for
diabetes management. Haemoglobin in the red blood cells
interacts with blood glucose to form glycated haemoglobin
(HbA1c), a stable Amadori adduct that serves as a reliable indi-
cator of individual glycemic status over 120 days.1 Because of its
usefulness as a good gauge for diabetes care, HbA1c levels should
be constantly monitored. In fact, the methodology for HbA1c
detection diﬀers between laboratory and point-of-care testing.
Laboratory-based HbA1c detection methods, such as cation-
exchange HPLC, aﬃnity chromatography, and capillary electro-
phoresis,2 involve bulky and expensive instruments and require a
long turnaround time. In contrast, advances in technology that
resulted in fast, easy-to-use, point-of-care (POC) HbA1c analyzers
oﬀer a better alternative for on-site facilitation to reduce patient
inconvenience for better diabetes management.
To enhance the on-site facilitation for diabetes care, the
attempt to develop POC devices for HbA1c detection nevere, University of Malaya, 50603 Kuala
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ubang Kerian, Kelantan, Malaysiaceases. In general, HbA1c biosensors can be categorized into
biosensors that directly detect HbA1c or fructosyl valine (FV, a
peptide generated from HbA1c proteolysis)-based biosensors.
With the advent of nanotechnology, more HbA1c biosensors
were designed and reported to possess outstanding analytical
performance. For example, a FV biosensor (which uses enzymes
as the biorecognition element) utilizing a zinc-oxide nano-
particles-polypyrrole lm for indirect detection of HbA1c was
reported to have enhanced stability and sensitivity compared to
previously reported FV biosensors.3 On the other hand,
biosensors that directly detect HbA1c can be further categorized
as amperometric, potentiometric, and piezoelectric biosensors
and biochips.4 In fact, with the discovery of more biomarkers for
diﬀerent diseases, eﬀorts to increase the specicity and
sensitivity to detect the biomarkers have led immunoassay-
based devices to become more clinically relevant.5 Hence, most
of the fabricated biosensors reported that operate based on the
electrochemical principle (owing to the ease of miniaturizing
the devices at high sensitivity) typically involve anti-HbA1c
antibodies as the bio-recognition element. For example, a
potentiometric HbA1c immunosensor using mixed SAM (Self
Assembled Monolayer)-wrapped nanospheres was reported to
possess good consistency in a clinical setting, in a miniaturized
form.6 Other than electrochemical immunosensors, SPR
(surface plasmon resonance) biosensors7 and antibody
microarrays8 were reported to detect HbA1c as well. While
maintaining high sensitivity in HbA1c detection, the reported
biosensors mostly involved expensive installation cost for
instrumentation, professionals to decipher the results
obtained, and a series of elaborated sampling procedures that
could compromise the rapidity to generate results. In fact, the
antibody-based microarrays reported involved a long incuba-
tion time of 2 hours,8 rendering the approach of detection not
suitable for routine diabetes management. For POC devices to
be useful as a diabetes care tool where type 2 diabetes is prev-
alent, especially in resource-limited settings, relatively inex-
pensive technology with the ease of sampling, testing, and
interpreting procedure is needed.
As simple as the urine pregnancy test strip, our lateral ow
HbA1c immunosensor is aimed to be user-friendly with rela-
tively easy sampling, testing, and subsequent interpreting
procedure. A dened volume of diluted blood sample was
owed through a lateral ow assay matrix where HbA1c was
captured at the test line due to the immunoreaction with anti-
HbA1c antibodies; subsequently colloidal gold-functionalized
anti-haemoglobin antibodies will generate visible test line(s).
Before the application of the approach, the ideal blocking
reagents, the test line format, the selectivity of the assay and the
potential interference from the colour of the blood sample were
studied. With the calibration curve established between the test
line intensity and HbA1c levels, the feasibility to perform
measurements using the lateral ow immunosensor was
demonstrated.
2. Materials and methods
2.1 Reagents and materials
The capturing antibody (monoclonal anti-haemoglobin A1c
IgG1 antibody), the detecting antibody (monoclonal anti-hae-
moglobin IgG1 antibody), and the puried HbA1c, HbA0, and
glycated HbA0 were purchased from Fitzgerald Industries
International (Acton, MA, USA); the secondary antibody (poly-
clonal goat-anti-mouse IgG antibody) was obtained from
Thermo Fisher Scientic Inc. (Waltham, MA, USA); gold nano-
particles (40 nm) were purchased from Kestrel Biosciences Co.,
Ltd (Pathumthani, Thailand); bovine serum albumin was
purchased from Amresco LLC (Solon, OH, USA); and 10%
western blocking reagent was obtained from Roche Diagnostics
(Selangor, Malaysia). The calibrators and haemolysis reagent
were purchased from Kamiya Biomedical Company (Seattle,
WA, USA). All other chemicals were purchased from Sigma-
Aldrich (Selangor, Malaysia). Phosphate buﬀer (containing
Na2HPO4 and NaH2PO4) was prepared at pH 7.4 by usingMilli-Q
water with a resistivity of 18.2 MU cm. NaCl, K2CO3, and HCl
were diluted using Milli-Q water; all other reagents were diluted
with the prepared phosphate buﬀer. The pH was adjusted to pH
7.4 to correspond to the normal physiological pH range between
7.35 and 7.45 in human blood.9 Because of diﬀerent matrices
involved in optimization studies, distinctive reagents were
needed to perform dilutions. For gold conjugates, blocking
reagents and selectivity tests which involved puried proteins
(i.e. antibodies, bovine serum albumin, and puriedhaemoglobin species etc.) that are sensitive to pH changes, the
pH-adjusted phosphate buﬀer that resembles physiological pH
was used. On the other hand, to lyse the erythrocytes
completely, interference studies and real sample analysis that
involved whole blood required a haemolysis reagent (distilled
water with stabilizers). Also, in order to maintain the matrix
similarity between whole blood and calibrators purchased, the
haemolysis reagent was used to perform dilution to generate the
calibration curve in the studies. Laminated nitrocellulose
membrane card (ref. HF135MC100), cellulose ber pads (ref.
CFSP173000) and glass ber pads (ref. GFCP083000) were
purchased from Merck Millipore (Selangor, Malaysia). For the
studies that involved blood testing, informed consent was
obtained from patients recruited and the study protocol was
implemented in accordance with the institutional medical
ethics board committee.
2.2 Apparatus
The absorbance of the gold conjugates before and aer treat-
ment with 10% NaCl was measured at a wavelength of 530 nm
using an Innite® M200 PRO microplate reader (Tecan Group
Ltd, Ma¨nnedorf, Switzerland). Signals on the immunosensor
were measured with an ESEQuant lateral ow reader (Qiagen
Lake Constance GmbH, Stockach, Germany). Prior to manual
lining of capture reagents on strips using a pipette, lateral ow
strips were cut using a Matric 2360 programmable shear from
Kinematic Automation (Twain Harte, USA).
2.3 Construction of lateral ow strips
2.3.1 Conjugation of gold nanoparticles to antibodies.
Optimization of the gold nanoparticle-conjugated anti-haemo-
globin-antibody was performed using a occulation assay
described by Thobhani et al.10 In this assay, the optimum pH
and the minimal antibody concentration required to stabilize
the gold conjugates were determined. First, the stability of gold
conjugates was tested by varying the pH of gold nanoparticles in
the range of 5.0 to 9.0 (adjusted using K2CO3), at a constant
antibody concentration of 30 mg mL1. The absorbance of the
gold conjugates before and aer treatment with 10% NaCl was
measured at a wavelength of 530 nm using an Innite® M200
PRO microplate reader (Tecan Group Ltd, Ma¨nnedorf, Switzer-
land). To determine the ideal concentration of antibody that
solvates the gold nanoparticles, gold nanoparticles with
adjusted pH were titrated with diﬀerent antibody concentra-
tions, and the stability of the gold conjugates was assessed as
described above. Once the ideal concentration of antibody and
pH were determined, gold conjugates were produced on a large
scale and diluted to OD 8 (to generate visually interpretable
lines without compromising the release time from the conju-
gate pad) to be deposited onto the conjugate pad of the strips.
2.3.2 Optimization of blocking reagents. Blocking reagents
are important to eliminate the non-specic binding of protein
on the NC membrane and to minimize the interference of the
background noise from nonspecic binding on the test strip. In
search of the ideal blocking reagent for our immunosensor,
industrial polymers such as polyvinylpyrrolidone (PVP) and
polyvinyl alcohol (PVA), carrier proteins such as casein in the
western blocking reagent (WBR), and bovine serum albumin
(BSA) were tested. Ten microliters of puried HbA1c (0.1 mg
mL1) (Fitzgerald Industries Inc., Acton, MA, USA) was
dispensed onto fully assembled lateral ow test strips (positive
test strips), and to determine the background generated, a
corresponding negative control strip (blocked with the same
blocking reagent) was tested with 10 mL of phosphate buﬀer
substituted for the puried HbA1c. The signals generated from
positive test strips and corresponding negative control strips
(blocked with diﬀerent blocking reagents) were then measured
using an ESEQuant lateral ow reader (Qiagen Lake Constance
GmbH, Stockach, Germany). The ratio of the signal to back-
ground was calculated by dividing the background (signal
generated on negative control strips) using the signal generated
on positive test strips.
2.3.3 Preparation of lateral ow strips. The lateral ow
strip consists of four overlaying components (the buﬀer appli-
cation pad, the conjugate pad, the laminated nitrocellulose
membrane, and the absorbent pad). It allows the test to be run
by capillary ow along the strip. The nitrocellulose membrane
contains three test lines, where the capturing antibody (mono-
clonal anti-HbA1c IgG1 antibody) was deposited (Fig. 1). A
control line, which contains polyclonal goat-anti-mouse IgG
antibody, was created as an internal control of the lateral ow
strip. The capturing antibody lined on the strips was dried for at
least 30 min in a desiccator before blocking was performed.
With four components overlaying each other at 2 mm in length,
the lateral ow strip at 4 mm in width was fully assembled aer
the strip was lined with the capture antibodies and blocked with
the optimized blocking reagent (please see Section 2.3.2 forFig. 1 Schematic of the fabrication of the HbA1c lateral ﬂow immunosen
formed on the nitrocellulose membrane in the fabrication of the hemogoptimization of blocking reagents). A dened amount of diluted
samples (calibrators or whole blood) of 10 mL was rst
dispensed directly onto the laminated nitrocellulose
membrane. Following application of the washing buﬀer (50 mM
phosphate buﬀer, pH 7.4, with 5% Tween-20), the gold conju-
gates on the conjugate pad were mobilized to react with the
antigen (HbA1c) and capture antibodies on the nitrocellulose
membrane. The non-reacted gold conjugates and antigens
(HbA1c) will then be mobilized to the absorbent pad.
2.3.4 Selectivity and interference test. In the selectivity test,
glycated species of HbA0, HbA0 and HbA1c were diluted to 0.1
mg mL1 with phosphate buﬀer (0.01 M, pH 7.4) prior to the
test. Then, 10 mL of HbA1c, HbA0, and glycated species of HbA0
were dispensed directly onto the NC membrane. Washing
buﬀer (50mMphosphate buﬀer, pH 7.4, with 5% Tween-20) was
applied to mobilize the gold conjugates and antigens (glycated
species of HbA0, HbA0, or HbA1c) to complete the assay.
To assess the specicity of the signal generated on the
nitrocellulose (NC) membrane, an interference test was con-
ducted. A control strip with a conjugate pad dried with 1 mg
mL1 monoclonal anti-haemoglobin antibody (IgG1, without
conjugation to gold nanoparticles) was prepared. For compar-
ison, the control strip and test strip (with the conjugate pad
containing gold-conjugated-monoclonal anti-haemoglobin
antibody) were tested with 10 mL of a 1 : 5 dilution of whole
blood. Aer direct dispensing of the diluted whole blood onto
the strips, the strips were washed with washing buﬀer.
2.3.5 Optimization on test lines and dilution factors. The
amount of test lines was optimized for ideal identication of
diﬀerent HbA1c levels in blood samples. Strips were either lined
with one, two, or three lines of monoclonal anti-HbA1c antibodysor. (A) Top view of the HbA1c immunosensor. (B) The sandwich format
lobin A1c immunosensor.
Fig. 2 (A) Selectivity test. Puriﬁed HbA1c (strip 1), puriﬁed glycated
species of HbA0 (strip 2) and puriﬁed HbA0 (strip 3) were tested on the
developed hemoglobin A1c immunosensor. No cross-reactivity was
observed from the glycated species of HbA0 (strip 2) and non-glycated
hemoglobin (HbA0) (strip 3), indicating that the immunosensor
developed was very speciﬁc to HbA1c. (B) Interference test. Strip 4 is
the developed hemoglobin A1c immunosensor while strip 5 was the
control strip with anti-hemoglobin antibody without conjugation to
gold nanoparticles, Fig. 2B shows that the signal generated from the
assay was only from the bound gold conjugated-anti-hemoglobin
antibody, the whole blood did not contribute to the redness observed
either on the test lines, or the control line.with one control line consisting of polyclonal goat-anti-mouse
antibody. Three concentrations of HbA1c were selected for
testing. In the preliminary study on test lines optimization, the
4.6%, 6.0%, and 7.6% calibrators were diluted ten times (with
the haemolysis reagent), and 5 mL of that dilution was directly
dispensed onto half dipsticks (without the buﬀer application
pad). Then, the half dipsticks were immersed into 10 mL of gold
conjugates, followed by 100 mL of phosphate buﬀer to complete
the test.
Due to the viscosity of the whole blood samples, the
dilution factor used was very critical not only to lyse the
cellular content of whole blood to release HbA1c, but also to
improve the uidity of whole blood on the test strip. The
haemolysis reagent containing blood stabilizers was used to
perform manual dilutions on whole blood and calibrators.
Calibrators (lysed packed human red blood cells) with
assigned values (4.6%, 6.0%, 7.6%, 9.1%, 10.7%, and 15.1%)
of HbA1c were tested for diﬀerent dilution factors to deter-
mine the quality of the calibration curve produced. Once the
dilution factor was identied with calibrators, assessed by
the quality of the calibration curves generated, the same
dilution factor was used to determine the ideal dilution
factor for whole blood testing on our immunosensor.
3. Results and discussion
3.1 Design and principle of the lateral ow immunosensor
The lateral ow immunosensor was designed to meet the
demand for sustainable diabetes care in a resource-limited
setting. The HbA1c biosensor was made of paper and, with
large-scale production, the cost of the test strip can be within
the range of $0.10 to $3.00 (depending on the antibody
production cost),11 which makes it relatively inexpensive. Our
HbA1c lateral ow immunosensor consists of a sample pad,
conjugate pad, nitrocellulose (NC) membrane, and absorbent
pad. On the NC membrane, three test zones contain the
capturing antibody for semi-quantitative, visually interpretable
HbA1c detection, while a control zone with the secondary
antibody (goat anti-mouse antibody) serves as an internal
control for each test strip (Fig. 1). In our lateral ow HbA1c
immunosensor, we chose to perform the detection in the
sandwich format (Fig. 1), which is known to be a more selective
and sensitive way to detect molecules with more than one
epitope.12 Haemoglobin consists of four subunits, and HbA1c is
formed via glycation of the terminal valine residue in b
subunit(s).13 Because HbA1c constitutes only a small fraction
(approximately 5%) of the total haemoglobin14 (for a detailed
description on the biological aspect of the haemoglobin pool,
please refer to Ang et al.15), to amplify the test signal, we chose
the anti-haemoglobin antibody as the detecting antibody. To
maintain the specicity and selectivity of our assay, the anti-
haemoglobin A1c (HbA1c) antibody was immobilized on the NC
membrane as the capturing antibody (Fig. 1b). As the sample
ran through the assay, the capturing antibody binds the
glycated epitopes exposing the non-glycated sites or non-
specic glycation sites (non-terminal valine residues in b
subunits or other residues in any haemoglobin subunits), whichwere then recognized by the gold nanoparticle (40 nm)-conju-
gated detecting antibody, thus generating a signal at the test
zone(s).3.2 Haemoglobin A1c immunosensor evaluation
3.2.1 Selectivity and interference test. To evaluate the
selectivity of the assay, diluted puried non-glycated haemo-
globin (HbA0), glycated species of HbA0 (which consists of
glycation sites other than b-chain N-terminal valine) and hae-
moglobin A1c (HbA1c) were tested. Because the gold conju-
gated-anti-haemoglobin antibody binds specically to
haemoglobin, the selectivity test is thus necessary to make sure
that the signals generated on the NCmembrane are purely from
glycated haemoglobin (HbA1c). Non-glycated haemoglobin and
other glycated species can bind to the gold conjugated-anti-
haemoglobin antibody, hence posing the chance to generate
false positive results on the strip. Other than that, because
glycation can occur at other amino acids, the selectivity of the
anti-HbA1c antibody towards the glycation site at b-chain N-
terminal valine is important to ensure that the signal is
specically from HbA1c in samples. To ensure the selectivity in
detection of HbA1c, puried HbA1c (human haemoglobin gly-
cated at b subunit N-terminal valine), glycated species of HbA0
(glycation sites other than the b-chain N-terminal valine) and
non-glycated haemoglobin (HbA0) were tested on the haemo-
globin A1c immunosensor that was developed. As shown in
Fig. 2A, strip 2 with glycated species of HbA0 and HbA0 (strip 3)
showed no signal on the immunosensor, indicating that the
developed immunosensor was very selective to HbA1c. Hence,
the test lines that showed up in the immunosensor were
representative of the presence of HbA1c (Fig. 2A).
Because the whole blood samples are red in colour, there was
a possibility that the signals generated on the test lines on the
developed immunosensor were contributed partly by the
redness of the whole blood sample. While the measurement of
the reectance on test lines can be performed using the
ESQuant lateral ow reader, which is designed to be specic for
detecting gold conjugates, the visual interpretation by house-
hold end-users can be cumbersome without the reader if blood
interferes with the colour generated on the test lines. From our
study, we noticed that the background colour of whole blood
did not contribute to the colour generated on the test line (refer
to Fig. 2B); thus, the colour generated on the test line was solely
dependent on the bound gold conjugates. In short, it was
conrmed that our developed immunosensor is very specic to
HbA1c and only bound gold conjugates that formed “sand-
wiches” with HbA1c and the capturing antibody (monoclonal
anti-HbA1c antibody) will result in the visibility of the test lines.3.3 Optimization of experimental parameters
3.3.1 Optimization of gold conjugates. We improved the
detection sensitivity and specicity by optimizing the genera-
tion of stable gold conjugates. To determine the ideal condi-
tions to synthesize stable gold conjugates, a occulation assay
was performed as described in Section 2.3.1. In the occulation
assay, electrolytes such as sodium chloride were used to mask
the charges on the gold nanoparticles, causing the disruption in
attraction and repulsive forces, resulting in gold nanoparticles
collapsing and aggregating to show visual changes in colour.10Fig. 3 (A) The variation of the colors across a range of pH, after the treat
unstable, indicated by the purplish blue color. (B) Absorbance decrease ve
gold conjugates was identiﬁed as 8.0. (C) Absorbance decrease versus det
the anti-hemoglobin antibody was determined to be the least concentra
bars display the standard deviation of triplicates for each data point.On the other hand, the presence of the proteins inhibits the
aggregation of gold nanoparticles by absorbing to the surface of
the gold nanoparticles.10 Hence, the smaller the diﬀerence in
absorbance before and aer treatment with 10% NaCl (termed
as absorbance decrease), the better is the conjugation of
proteins onto the surface of the gold nanoparticles and there-
fore the higher the stability of the gold conjugates. By per-
forming the occulation assay, we found out that at pH 8.0, with
a concentration of 30 mg mL1 of the anti-haemoglobin anti-
body, the gold conjugates formed had the least absorbance
diﬀerence (Fig. 3). Therefore, this indicated that gold conju-
gates were very stable under the specied conditions, which
were utilized later to prepare gold conjugates on a large scale for
deposition onto conjugate pads to assemble a full haemoglobin
A1c immunosensor.
3.3.2 Optimization of blocking reagents. To eliminate the
high background, diﬀerent types of blocking reagents were
tested in the assay to select the optimal blocking buﬀer for the
test strips. An ideal blocking buﬀer should be able to reduce the
background noise while providing concentration-dependent
detection of the analyte, i.e., HbA1c. In our case, 1% of the
western blocking reagent (WBR), which contains casein, was
shown to eﬃciently block the unwanted non-specic signal.
Little to no background was observed on the negative control
strips (strips tested with phosphate buﬀer in place of puried
HbA1c) blocked with 1% WBR. On the other hand, the
unblocked strips or blocked strips with other blocking reagents
(polyvinylpyrrolidone (PVP) and polyvinyl alcohol (PVA), bovine
serum albumin (BSA), and a mixed blocking reagent thatment of 10% NaCl. The gold conjugates formed at pH 5 and pH 6 were
rsus pH (measured at 530 nm). The optimumpH to solvate and stabilize
ecting antibody concentrations (measured at 530 nm). 30.0 mgmL1 of
tion of antibody needed to form stable gold conjugates at pH 8.0. Error
consisted of 1% BSA, 0.02% polyvinylpyrrolidone (PVP), 0.05%
casein, and 0.002% Tween-20 in 1 Tris-buﬀered saline (pH
7.4)) yielded a high signal in negative control strips, indicating
that the signal observed from the positive test strips (strips
tested with puried HbA1c) did not necessarily originate from
the binding of HbA1c (Fig. 4). In most lateral ow studies, the
remaining protein-binding sites on the NC membrane can be
blocked eﬃciently by BSA (bovine serum albumin);16–18 however,
our test strips showed signicant interference from the back-
ground noise (non-specic binding) when the strips were
blocked with BSA. In other words, BSA and other blocking
reagents did not suﬃciently block the protein-binding sites on
the strips. On the other hand, 1% WBR-blocked strips which
had little to no signal on negative control strips, indicated that
1% WBR is the best blocking reagent for our test strips, similar
to the observation by Ang et al.19 Therefore, we can then be
condent that the signal generated from the immunosensor
blocked with 1% WBR was specically originating from HbA1c
“sandwiched” between the gold conjugated-anti-haemoglobin
antibody and anti-HbA1c antibody.Fig. 4 Signal to background ratio vs. blocking reagents. All the
blocking reagents were prepared in dilution using 0.01 M phosphate
buﬀer, pH 7.4. Mixed blocking buﬀer was prepared using 1% BSA,
0.02% polyvinylpyrrolidone (PVP), 0.05% casein, 0.002% Tween-20 in
1 Tris-buﬀered saline (pH 7.4). All the other blocking buﬀers, except
1% WBR (western blocking reagent), resulted in a visually detectable
signal on strips. 1% WBR was thus selected as the best blocking buﬀer
for our fabricated HbA1c immunosensor. Error bars represent standard
deviation triplicates associated with each data point.
Fig. 5 (A) Strips with the 1-test line format tested with increasing conc
increasing concentration of HbA1c. (C) Strips with the 3-test line format3.3.3 Optimization of test lines. To achieve visual inter-
pretation of HbA1c levels based on the number and the inten-
sity of the test lines shown, the test zone on the NC membrane
was expanded to contain three lines of the immobilized
capturing (HbA1c-specic) antibody for the sandwich reaction.
As the rst test line was saturated, the remaining HbA1c moved
to the next line, where it is again sandwiched between the
capturing and detecting antibodies; thus, the concentration of
HbA1c in a sample can be assessed by the number and colour
intensity of the lines in the test zone(s). Optimization of test
lines involved testing on diﬀerent formats to determine which
format would allow for a more user-friendly interpretation,
without the requirement of a lateral ow reader for measure-
ment. Fig. 5A–C show diﬀerent test line formats across diﬀerent
concentrations of HbA1c. While the interpretation of intensity
can be very subjective, we found that the number of lines better
aided the visual interpretation. It is important to note that one-
(Fig. 5A) and two-line formats (Fig. 5B) showed a gradient of
intensity across an increasing concentration of HbA1c; however,
it was subjective to tell which strip has the darker or more
intense test line(s) with either the one- or two-line format. On
the other hand, the three-line format allowed a clear interpre-
tation of the strip tested with higher levels of HbA1c. The least
concentrated HbA1c (4.6%) had not only a less intense rst test
line, but the 2nd and 3rd test lines were almost invisible, leaving
a good intensity gap for the next higher level (6.0%) of HbA1c
tested for the ease of distinguishing (Fig. 5C). To distinguish
between the 6.0% and 7.6% HbA1c in the three-line format, the
third line was the determining line. Because all three lines
showed up, we relied on the intensity of the 3rd line to judge
which strip had a higher level of HbA1c tested. The third line
clearly showed up with a higher intensity in the strip with a
higher level of HbA1c. In short, we decided to use the three-line
format for better visual interpretation in the household setting.
3.3.4 Generation of calibration curves. To measure HbA1c
levels in blood samples, the relationship between the signal
intensity and HbA1c levels was investigated using commercial
calibrators. To generate a calibration curve for quantitative
analysis, six points of HbA1c concentrations that covered 4.6%
to 15.1% HbA1c were used. Optimization at diﬀerent dilutions
was performed to determine the best calibration curve to
perform the quantitative analysis. The calibrators were
purchased (lysed human erythrocytes) with designated HbA1centration of HbA1c. (B) Strips with the 2-test line format tested with
tested with increasing concentration of HbA1c.
values (4.6%, 6.0%, 7.6%, 9.1%, 10.7%, and 15.1%). Optimiza-
tion of the calibration curves was performed based on diﬀerent
dilution factors using the haemolysis reagent (water with
stabilizers). Another study by Chen et al. also reported on using
water to perform dilution on the whole blood sample prior to
testing.8 The calibration curves at diﬀerent dilutions demon-
strated distinct patterns, indicating that dilution factors can
directly aﬀect the immunosensor performance in terms of
sensitivity in our assay.
Fig. 6A–C show the overall detection range of the calibration
curves for diﬀerent dilution factors, while the insets of Fig. 6A–C
depict the linear dynamic range useful for future quantitative
HbA1c level measurements. Note that for undiluted calibrators,
the calibration curve generated had a low coeﬃcient of deter-
mination, R2, of 0.61 (inset of Fig. 6A), indicating that the linear
relationship between the HbA1c levels and the signal on the
assay was weak. Also, the standard deviations were consistently
large throughout the HbA1c levels tested (Fig. 6A). Since the
accuracy in quantication of the HbA1c levels by using a lateral
ow assay can oen be aﬀected by the sample composition
(matrix eﬀect),20 we presumed that the high viscosity of the
undiluted calibrators had contributed to the high degree of
variability for each test across the HbA1c levels (Fig. 6A). Hence,Fig. 6 (A) Signal intensity of test lines measured versus concentrations
versus concentration of HbA1c, at 1 : 2 dilutions. (C) Signal intensity of tes
bar represents the standard deviation for triplicates of each data point. (D
dilution factors. 1 to 6 indicated the increasing HbA1c levels (1 : 4.6%; 2we concluded that the assay could be saturated with undiluted
calibrators and therefore optimization on the dilution factors
was necessary to create a calibration curve. By diluting the
calibrators at 1 : 2 (inset of Fig. 6B) and 1 : 5 (inset of Fig. 6C)
dilution factors, we found that the resultant calibration curves
yielded a reasonably good t within the range of 4.0% (20 mmol
mol1) to 12.0% (108 mmol mol1) HbA1c. In comparison, with
both 1 : 2 and 1 : 5 diluted calibration curves in the same range
for linear detection (4.0% to 12.0%), the 1 : 2 diluted calibration
curve assumed a higher R2 of 0.95, while the 1 : 5 diluted curve
showed a R2 of 0.78. However, with the consideration of a better
assay time (1 : 2 diluted calibrators took 45 min to eliminate the
background for analysis, 1 : 5 diluted calibrators required as
low as 20 min to be ready for measurement) for better sensitivity
observed across the HbA1c levels (assessed by the higher slope
of the linear graph and the visual interpretation shown in the
inset of Fig. 6D), we decided that the 1 : 5 diluted calibration
curve was the best calibration curve to perform future quanti-
tative analysis.
The results showed that the calibration curve at 1 : 5 dilution
assumed a reasonably good t with the highest sensitivity to
establish a linear relationship between the signal and HbA1c
levels within the range of 4% (20 mmol mol1) to 12%of HbA1c, without dilution. (B) Signal intensity of test lines measured
t lines measured versus concentration of HbA1c, at 1 : 5 dilutions. Error
) Visual representation of strips tested with the calibrator diluted at 1 : 5
: 6.0%; 3 : 7.6%; 4 : 9.1%; 5 : 10.7%, and 6 : 15.1%).
Fig. 7 (A) Dilution factors 1 to 2, 1 to 5, and 1 to 10 were tested to determine the ideal dilution factor for whole blood. Note: picture shown after
20 min of washing. (B) The hemoglobin A1c immunosensor tested with whole blood at 1 to 5 dilution factor, with three diﬀerent concentrations
(strip 1: 5% HbA1c; strip 2: 6.5% HbA1c; strip 3: 9.9% HbA1c).(108 mmol mol1) of HbA1c. The linear concentration range
between 4% and 12% HbA1c contained the critical treatment
goal values of 6.5–7% HbA1c and therefore meets the demands
of eﬃcient diabetes control. However, there was a limitation for
a semi-quantitative analysis via visual interpretation based on
the number of test lines and its intensity beyond 9.1% HbA1c.
As all the three test lines appeared and the degree of the
intensity was quite similar aer 9.1% HbA1c (Fig. 6D), it could
be diﬃcult for the end user to distinguish a higher level of
HbA1c beyond this point. Nonetheless, by using the lateral ow
reader to perform a quantitative measurement, the signal
intensity of the test lines was found to be increasing in a HbA1c-
dependent way beyond 9.1% of the HbA1c level.3.4 Lateral ow immunosensor for real sample analysis
(HbA1c in whole blood)
While the calibration curve is very useful to assess HbA1c levels
in whole blood, it is also very important for the blood to readily
ow through the strips without extensive and prolonged pre-
treatment. Our study focused on measuring HbA1c levels in
whole blood, which can oen be too viscous to readily ow
through the lateral ow test strips. To resolve this problem,
manual dilution is required. In our experiment, the dilution of
whole blood samples obtained from the University of Malaya
Medical Center (UMMC) was performed with a haemolysis
reagent (distilled water with blood stabilizers). The diluted
whole blood (10 mL) was dispensed directly onto the NC
membrane, which was washed with phosphate buﬀer contain-
ing Tween-20. At a 1 : 2 dilution, whole blood remains viscous to
ow through the assay via capillary reaction. On the other hand,
whole blood at a 1 : 10 dilution owed readily across the assay
matrix; however, the test lines generated were too weak for
visual interpretation. Our results indicated that whole blood
samples yield a HbA1c level-dependent signal at a dilution
factor of 1 : 5 (Fig. 7A). A 1 : 5 dilution was the ideal dilutionfactor for whole blood to ow readily across the assay matrix
with a low background while generating a visually interpretable
signal within a reasonable assay time of approximately 25 min.
Once the ideal dilution factor was determined to be at 1 : 5,
we performed a preliminary test on the whole blood samples
that have diﬀerent HbA1c values (5.5%, 6.5%, and 9.9%HbA1c).
As shown in Fig. 7B, strip 1 tested with 5.5% HbA1c had only
two test lines, a clear indication that it had the lowest HbA1c
value tested. To distinguish which had higher HbA1c value
tested, strip 3 (tested with 9.9% HbA1c) was shown to have
higher intensity across all three test lines compared to strip 2
(tested with 6.5% HbA1c), thus reecting that the HbA1c levels
tested were highest among all of the strips. Hence, for diabetic
patients with inadequately controlled blood glucose, i.e., for
those with HbAlc levels >6.5% (ref. 21) (or >7% in the United
States22), the immunosensor will show intense dark red colour
in all of the test zones, suggesting that immediate medical
attention is needed. With distinctive patterns observed on the
strip tested with groups of blood samples with diﬀerent HbA1c
levels, our immunosensor showed promising performance as a
useful point-of-care device that caters to the need of user-
friendly and inexpensive technology for better diabetic care in
resource-limited settings.4. Conclusions
In this work, we have manufactured a lateral ow HbA1c
immunosensor that is simple, economical, and portable. The
haemoglobin A1c lateral ow immunosensor has been opti-
mized so that the gold conjugates were stabilized at pH 8.0, 30
mg mL1, and the ideal blocking reagent for the immunosensor
was found to be 1% western blocking reagent (containing
casein). In addition, the immunosensor was found to generate a
specic signal fromHbA1c, where blood colour did not interfere
with the colour shown on the test lines and the control line. To
quantify the whole blood samples, the calibration curve at 1 : 5
dilution was found to be the ideal curve for the quantitative
analysis.
With simple dilution from nger-prick blood, our prototype
can be used with a standard image set (a similar concept to the
pH paper colour scale) for certain ranges of HbA1c levels
(normal range <6.0% HbA1c, under control range 6.5% to 7.0%
HbA1c, elevated and needing medical attention range >7.0%
HbA1c) where the patient can compare the colour intensity and
interpret the result visually. With the construction of the cali-
bration curve, future quantitative analysis can be conducted
alongside with a lateral ow reader. We anticipate that our
design developed here can be integrated with inexpensive
detection technology like smartphone-based imaging23 to
enable point-of-care rapid evaluation for numerical results on
HbA1c levels, thereby better facilitating on-site diabetes care in
resource-limited settings.
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